通过向氧酶增殖器激活受体来治疗NASH
Bart Staels1, Laura Butruille1, Sven Francque2
1University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
Journal of hepatology
|July 17, 2023
概括
同时激活过氧体增殖器激活受体 (PPAR) 显示了对非酒精性脂肪肝炎 (NASH) 的增强治疗潜力. 准多个PPAR为NASH和相关疾病提供了更大的临床疗效.
科学领域:
- 肝病学和代谢疾病研究.
- 分子和细胞生物学.
- 药理学和药物发现.
背景情况:
- 非酒精性脂肪肝炎 (NASH) 涉及复杂的代谢,炎症,血管和纤维素性途径.
- 过氧体增殖器激活受体 (PPAR) 是核受体,调节对代谢和炎症变化的适应.
- PPARs在NASH病变发生过程中发挥着至关重要的作用.
研究的目的:
- 探索NASH同时PPAR同型激活的治疗潜力.
- 为了评估与单个向药物相比,多个PPAR激动剂的增强疗效.
- 为了研究对NASH相关肝脏和肝外疾病的影响.
主要方法:
- 对NASH中PPAR激动剂的临床前和临床数据的审查.
- 对NASH中PPAR同型调节的基础机制的分析.
- 对NASH解决和纤维化回归的组织学终点的评估.
主要成果:
- 单个PPAR激动剂显示了临床前的抗NASH活性,但临床效果适度.
- 同时激活多个PPAR异型,表明治疗潜力增强.
- 一些多种PPAR激动剂在改善NASH组织学终点方面表现出临床有效性.
结论:
- 通过同时激活PPAR而产生的类作用增强了NASH的药理潜力.
- 多重PPAR激动剂代表了NASH和相关疾病的有前途的治疗策略.
- 对于NASH治疗,需要对多种PPAR激动剂进行进一步的临床研究.
相关概念视频
Peroxisomes
13.6K
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
13.6K
Transducer Mechanism: Nuclear Receptors
1.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K
Protein Import into the Peroxisomes
3.6K
Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
3.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
218
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218


